Difference between revisions of "Profiles"
Jump to navigation
Jump to search
Line 11: | Line 11: | ||
*<td nowrap>[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023Dec19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023 <b>DOI:10.1148/QIBA/20231219</b> ]] | *<td nowrap>[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023Dec19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023 <b>DOI:10.1148/QIBA/20231219</b> ]] | ||
− | *[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022]] | + | *<td nowrap>[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022 <b>DOI:10.1148/QIBA/20220721</b>]] |
*<td nowrap>[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022 <b>DOI:10.1148/QIBA/20221215</b>]]</td nowrap> | *<td nowrap>[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022 <b>DOI:10.1148/QIBA/20221215</b>]]</td nowrap> |
Revision as of 18:14, 11 July 2024
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023 DOI:10.1148/QIBA/20230615
- PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)